TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26047615

Group type: EXPERIMENTAL
Intervention: Eurythmy therapy A (EYT-A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eurythmy therapy B (EYT-B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control exercise 1 (CE1-A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control exercise 2 (CE2-A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control exercise 1 (CE1-B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control exercise 2 (CE2-B)
Number of subjects: 20
Study: 23612620

Group type: EXPERIMENTAL
Intervention: Internal jugular vein catheter placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subclavian vein catheter placement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both internal jugular and subclavian vein catheter placements
Number of subjects: 40
Study: 21159892

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 19835475

Group type: EXPERIMENTAL
Intervention: High concentrations of interleukin 15 (IL-15) in breast milk
Number of subjects: 94

Group type: COMPARATOR
Intervention: Breast milk from HIV-infected women who transmitted HIV
Number of subjects: 94
Study: 17353580

Group type: EXPERIMENTAL
Intervention: Pomace olive oil (POO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Refined olive oil (ROO)
Number of subjects: 9
Study: 12955284

Group type: EXPERIMENTAL
Intervention: Balanced amino-acid mixture (BAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TYR-free mixture (absence of tyrosine and phenylalanine)
Number of subjects: 0
Study: 11174342

Group type: EXPERIMENTAL
Intervention: Invasive approach (cardiac catheterization)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Noninvasive approach
Number of subjects: 202
Study: 9828235

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN-2b) 3 million units (MU) given subcutaneously three times per week for 12 months (group 2)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN-2b) 3 million units (MU) given subcutaneously three times per week for 6 months (group 3)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Interferon alfa-2b (IFN-2b) 3 million units (MU) given subcutaneously three times per week for 6 months (group 1)
Number of subjects: 247
Study: 7664547

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hypervolemia (5% albumin)
Number of subjects: 48
Study: 2653119

Group type: EXPERIMENTAL
Intervention: Cervical epidural anesthesia (CEA) with 15 ml of 0.375% bupivacaine and 150 micrograms fentanyl.
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia (GA) with 0.2 mg.kg‐1 flunitrazepam, 5 micrograms.kg‐1 fentanyl, intubation with 0.08 mg.kg‐1 vecuronium, and ventilation with nitrous oxide and oxygen (50% each). Further injections of 2 micrograms.kg‐1 fentanyl every 30 min.
Number of subjects: 20
Study: 902556

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose of alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium sensory stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High sensory stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No sensory stimulation
Number of subjects: 12
Study: 31466942

Group type: EXPERIMENTAL
Intervention: Smartphone-enabled video-observed treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Directly observed treatment
Number of subjects: 0
Study: 28358274

Group type: EXPERIMENTAL
Intervention: Cognitive training program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Coping skills group
Number of subjects: 62
Study: 26114220

Group type: EXPERIMENTAL
Intervention: Electronic text-message system
Number of subjects: 149
Study: 23934239

Group type: EXPERIMENTAL
Intervention: HCG injection before IUI
Number of subjects: 100

Group type: COMPARATOR
Intervention: HCG injection after IUI
Number of subjects: 100
Study: 20964739

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 382
Study: 19017883

Group type: EXPERIMENTAL
Intervention: Helium-hyperoxia (60:40 He:O2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Air
Number of subjects: 38
Study: 17416272

Group type: EXPERIMENTAL
Intervention: Talocrural joint manipulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo manipulation
Number of subjects: 52
Study: 15502456

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11454840

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with moderate dissection (group A)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Balloon angioplasty without moderate dissection (group B)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with stenting (group A)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Balloon angioplasty without stenting (group A)
Number of subjects: 256
Study: 9730451

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC) 30 mg, weekly for 4 weeks, then monthly for 5 months
Number of subjects: 344

Group type: COMPARATOR
Intervention: Intravesical bacille Calmette‐Guérin (BCG), weekly for 6 weeks
Number of subjects: 344
Study: 7986787

Group type: EXPERIMENTAL
Intervention: Vegan diet for 3.5 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 0
Study: 2487934

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 170

Group type: COMPARATOR
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plus 100 micrograms epidural fentanyl
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plus fentanyl plus epinephrine
Number of subjects: 170
Study: 8381

Group type: EXPERIMENTAL
Intervention: Three capsules containing 35 mg of ST-1435 (group A)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Four capsules of ST-1435 (group B)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Five capsules of ST-1435 (group C)
Number of subjects: 285
Study: 31477190

Group type: EXPERIMENTAL
Intervention: Family Connects postnatal nurse home visiting intervention
Number of subjects: 4777

Group type: COMPARATOR
Intervention: Services as usual (control)
Number of subjects: 4777
Study: 29310375

Group type: EXPERIMENTAL
Intervention: Topical administration of tetracycline ointment every 6 hours for 48 hours postoperatively
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no topical tetracycline)
Number of subjects: 117
Study: 25972817

Group type: EXPERIMENTAL
Intervention: Michael's game (MG)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 172
Study: 22494449

Group type: EXPERIMENTAL
Intervention: Medihoney™ dressings
Number of subjects: 121
Study: 22184800

Group type: EXPERIMENTAL
Intervention: Gum A (Nicorette Freshfruit)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Gum N (Nicorette Icy White)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Gum B (Nicotinell fruit)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Gum M (Nicotinell mint)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Gum Q (NiQuitin mint)
Number of subjects: 607
Study: 19404945

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone
Number of subjects: 199

Group type: COMPARATOR
Intervention: Single DMARD (initially sulfasalazine) with or without prednisolone
Number of subjects: 199
Study: 17380844

Group type: EXPERIMENTAL
Intervention: lercanidipine (10 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: hydrochlorothiazide (25 mg/day)
Number of subjects: 26
Study: 17278405

Group type: EXPERIMENTAL
Intervention: Correspondence emphasizing the legal obligation to report
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Correspondence emphasizing the public health benefits of reporting
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Correspondence emphasizing both the legal obligation and public health benefits
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group (receiving only the benefit message)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group (receiving only the obligation message)
Number of subjects: 368
Study: 13129444

Group type: EXPERIMENTAL
Intervention: Tomato lycopene oleoresin (30 mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 10323423

Group type: EXPERIMENTAL
Intervention: Senna (1 package diluted in a glass of water)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Polyethylene glycol (2 packages diluted in 2-3 L of water)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 523
Study: 7592201

Group type: EXPERIMENTAL
Intervention: Nose breathing supine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nose breathing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nose breathing with mouth held open
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Negative pressure application (0 to -12.5 cmH2O)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Negative pressure via nose
Number of subjects: 13
Study: 1902298

Group type: EXPERIMENTAL
Intervention: Diet supplemented with canned mackerel or herring containing long-chain n-3 fatty acids (EPA and DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet supplemented with canned herring (lower dose of n-3 fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet supplemented with n-3 fatty acids
Number of subjects: 0
Study: 6215008

Group type: EXPERIMENTAL
Intervention: Piperacillin (150 mg/kg/day for urinary tract infections; 250 mg/kg/day for other infections)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Carbenicillin (200 mg/kg/day for urinary tract infections; 450 mg/kg/day for other infections)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 107
Study: 29727016

Group type: EXPERIMENTAL
Intervention: Speed Endurance (SE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous Moderate-intensity (CM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Repeated-Sprint (RS)
Number of subjects: 12
Study: 26018112

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (100 mg daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) with Vitamin C
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no Vitamin C)
Number of subjects: 180
Study: 25740851

Group type: EXPERIMENTAL
Intervention: 100μg selenium-enriched yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 200μg selenium-enriched yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 300μg selenium-enriched yeast
Number of subjects: 491

Group type: COMPARATOR
Intervention: Matching yeast-based placebo tablets
Number of subjects: 491
Study: 23993469

Group type: EXPERIMENTAL
Intervention: Acarbose plus metformin fixed-dose combination (FDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acarbose monotherapy
Number of subjects: 0
Study: 20739581

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) suppressive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18437288

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of halphaCGRP (2 mug/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16428335

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piroxicam 20 mg daily
Number of subjects: 60
Study: 12892157

Group type: EXPERIMENTAL
Intervention: Vitamin D3 600 IU supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10993487

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: d-alpha-tocopherol (700 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both antioxidants (Q10 and d-alpha-tocopherol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9176650

Group type: EXPERIMENTAL
Intervention: Spacehaler with 200 micrograms salbutamol
Number of subjects: 25

Group type: COMPARATOR
Intervention: MDI plus Volumatic spacer with 200 micrograms salbutamol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Spacehaler
Number of subjects: 25

Group type: COMPARATOR
Intervention: MDI plus Volumatic spacer
Number of subjects: 25
Study: 1288514

Group type: EXPERIMENTAL
Intervention: Piroxicam + Ranitidine (300 mg nocte)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Piroxicam + Placebo
Number of subjects: 28
Study: 3885832

Group type: EXPERIMENTAL
Intervention: Metoprolol 15 mg intravenously followed by 200 mg daily orally
Number of subjects: 20
Study: 29090473

Group type: EXPERIMENTAL
Intervention: Quizartinib 40 mg/d (DL1; n = 7)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quizartinib 60 mg/d (DL2; n = 6)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 13
Study: 27515970

Group type: EXPERIMENTAL
Intervention: Tailored improvement program including communication skills training, online patient information, and a clinical protocol for managing depressive symptoms.
Number of subjects: 1782

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Tailored improvement program.
Number of subjects: 1782
Study: 23771807

Group type: EXPERIMENTAL
Intervention: Iron and vitamin D-fortified skimmed milk (Fe+D group, n = 55)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Iron-fortified skimmed milk (Fe group, n = 54)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual diet without supplementation (R group, n = 56)
Number of subjects: 165
Study: 23083673

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus LPR and Bifidobacterium longum BL999 (LPR+BL999)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: L paracasei ST11 and B longum BL999 (ST11+BL999)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 20029223

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patch (FP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Injection of local anesthesia (IP)
Number of subjects: 41
Study: 18387054

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 519

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 519

Group type: COMPARATOR
Intervention: Entecavir vs Lamivudine
Number of subjects: 519
Study: 15963867

Group type: EXPERIMENTAL
Intervention: Oral extended-release hydromorphone (HHER) administered q24h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release hydromorphone (HHIR) dosed four times daily
Number of subjects: 0
Study: 14673431

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs and supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chondroprotective supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viscosupplementation mechanism of HA
Number of subjects: 0
Study: 10545428

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CE) 0.625 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of CE and Vitamin E
Number of subjects: 28
Study: 8739514

Group type: EXPERIMENTAL
Intervention: GnRH agonist 300 micrograms
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GnRH agonist 600 micrograms
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 29
Study: 2009118

Group type: EXPERIMENTAL
Intervention: CPM 4-day group (6 h daily CPM for 4 days in hospital followed by intermittent passive motion at home)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CPM 14-day group (6 h daily CPM for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 6760676

Group type: EXPERIMENTAL
Intervention: amikacin plus ampicillin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: amikacin plus cephalotin
Number of subjects: 30

Group type: COMPARATOR
Intervention: amikacin plus ampicillin and amikacin plus cephalotin
Number of subjects: 30

Group type: COMPARATOR
Intervention: both regimens
Number of subjects: 30
Study: 31053067

Group type: EXPERIMENTAL
Intervention: Internet-based Global Protocol (includes BA and PPs components)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Internet-based BA Protocol (without PPs component)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Internet-based PPs Protocol (without BA component)
Number of subjects: 192
Study: 30522739

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 to 0.4 mg/kg (n = 22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls (n = 21)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Whole-brain analyses
Number of subjects: 42
Study: 26946057

Group type: EXPERIMENTAL
Intervention: Tandem high dose chemotherapy with epirubicin, cyclophosphamide, and thiotepa
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Induction with 2× epirubicin-cyclophosphamide followed by tandem HD chemotherapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Dose dense chemotherapy (4× epirubicin-cyclophosphamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil)
Number of subjects: 143
Study: 24057153

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 28
Study: 22728781

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol-opioid techniques
Number of subjects: 0
Study: 20460174

Group type: EXPERIMENTAL
Intervention: Alternative complex list based randomisation solutions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stratified randomisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced randomisation
Number of subjects: 0
Study: 17506136

Group type: EXPERIMENTAL
Intervention: VelaSmooth system treatment on one thigh
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control thigh (untreated)
Number of subjects: 16
Study: 15789316

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Remifentanil and Placebo)
Number of subjects: 20
Study: 11817917

Group type: EXPERIMENTAL
Intervention: Ultrasonography and photographs of atherosclerotic plaques (C group)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ultrasonography without photographs (B group)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No ultrasonography (A group)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ultrasonography (B + C)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Photographs of plaques (C)
Number of subjects: 153
Study: 10793229

Group type: EXPERIMENTAL
Intervention: Oral casokefamide at doses of 5.5, 8.0, and 16.0 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral casokefamide
Number of subjects: 10
Study: 8880681

Group type: EXPERIMENTAL
Intervention: Computer-based Physician Workstation (PWS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Existing hospital information system (Control)
Number of subjects: 37
Study: 1993412

Group type: EXPERIMENTAL
Intervention: Single dose of Timentin (3.1 g IV at commencement of operation)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Double dose of Timentin (3.1 g IV at commencement of operation and repeated after 2 hours)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Single dose of Timentin
Number of subjects: 271

Group type: COMPARATOR
Intervention: Double dose of Timentin
Number of subjects: 271
Study: 6877579

Group type: EXPERIMENTAL
Intervention: Kanji script; variations in physical size of numbers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kana script; variations in physical size of numbers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous performance with Kanji
Number of subjects: 0
Study: 30946377

Group type: EXPERIMENTAL
Intervention: BiOSS LIM C stent (dedicated bifurcation balloon expandable stent made of cobalt‐chromium alloy, releasing sirolimus 1.4 μg/mm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: limus second‐generation drug‐eluting stents (DES)
Number of subjects: 0
Study: 29462493

Group type: EXPERIMENTAL
Intervention: RT initiated >4 weeks post-op
Number of subjects: 1395

Group type: COMPARATOR
Intervention: RT initiated ≤4 weeks post-op
Number of subjects: 1395
Study: 26588232

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1 and 80 mg on days 2-3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fosaprepitant (150 mg, day 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fosaprepitant
Number of subjects: 20
Study: 24823715

Group type: COMPARATOR
Intervention: Saline only (group D0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bolus dose of 1.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 0.5 μg·kg(‐1) ·h(‐1) (group D1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bolus dose of 2.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 1.0 μg·kg(‐1) ·h(‐1) (group D2)
Number of subjects: 60
Study: 22926161

Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (B6, B9, B12)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (B6, B9, B12) in C allele carriers of MTHFR C677T variant
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (B6, B9, B12) in A allele carriers of MTRR A66G variant
Number of subjects: 206
Study: 21039835

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib vs Best supportive care
Number of subjects: 0
Study: 17661885

Group type: EXPERIMENTAL
Intervention: Interprofessional learning (IPL) pairs
Number of subjects: 160
Study: 15615740

Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14